ArticleBMC nursing2026
Nurse-led mobile health symptom management in patients with head and neck cancer undergoing concurrent chemoradiotherapy: a randomized controlled trial.
Article in BMC nursing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEarly identification and timely intervention of radiotherapy‑related toxicities are crucial for maintaining treatment adherence and improving quality of life in patients with head and neck cancer (HNC) undergoing concurrent chemoradiotherapy (CCRT). To address this clinical need, a nurse‑led smartphone application, Sun Yat-sen Symptom Management (SYS-SM), was developed to integrate patient‑reported outcome (PRO) assessments with personalized self‑management guidance tailored to individual symptom profiles. The feasibility and preliminary efficacy of this application were evaluated in a randomized controlled trial (RCT).
methodsEligible patients were randomly assigned to an intervention group or a control group. During the 3-month intervention period, the intervention group received standard care combined with nurse-led personalized mobile symptom management, whereas the control group received standard care alone. The intervention included in-person discharge education, structured instruction on application use, and automated push notifications delivering individualized health management recommendations based on PRO data. When symptom scores exceeded predefined thresholds, alerts were automatically generated for nursing staff. Clinical outcomes were assessed at baseline (T0), 1 month (T1), and 3 months (T2).
resultsA total of 136 patients were enrolled (107 [78.7%] men; mean [SD] age, 50.88 [12.6] years), including 67 participants in the intervention group and 69 in the control group, with no significant differences in baseline characteristics. For health-related quality of life (HRQOL), the primary summary scores showed no significant overall group × time interaction (P = 0.108; T2: mean difference [MD] = 4.61; 95% CI, -1.02-10.24; effect size [ES] = 0.23). In the physical functioning domain demonstrated a significant interaction effect (P = 0.048; T2: MD = 8.25; 95% CI, 1.15-15.35), its effect size (ES = 0.35) remained below the clinical threshold (ES ≥ 0.40). Notably, significant improvements were observed in several secondary domains, specifically appetite loss (interaction P = 0.001; ES = -0.56) and global health status (interaction P = 0.009; ES = 0.46). Improvements in self-efficacy (SUPPH interaction P = 0.012) and psychological status (IDA interaction P < 0.01) were significantly greater in the intervention group. The SYS-SM application demonstrated high feasibility and acceptability.
conclusionsA nurse-led personalized mobile health symptom management intervention did not significantly improve primary overall HRQOL summary scores, but it demonstrated targeted benefits in reducing specific symptoms (particularly appetite loss), enhancing self-management capacity, and alleviating negative affect in patients with HNC undergoing concurrent chemoradiotherapy. The application shows potential for broader clinical implementation.
trial registrationThe study was prospectively registered with the Chinese Clinical Trial Registry (ChiCTR2300072314) on June 9, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.